MedTrace Logo

Altitude Sickness Prevention With Ibuprofen Relative to Acetazolamide and Treatment Efficacy

NCT03154645 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2018-11-26

No results posted yet for this study

Summary

This double blind randomized trial will compare ibuprofen to acetazolamide for the prevention of acute mountain sickness. These drugs have never been directly compared for efficacy. The study population is hikers who are ascending at their own rate under their own power in a true hiking environment at the White Mountain Research Station, Owen Valley Lab (OVL) and Bancroft Station (BAR), Bancroft Peak, White Mountain, California.

Conditions

  • Acute Mountain Sickness

Interventions

DRUG

Ibuprofen

non-steroidal anti-inflammatory drug

DRUG

Acetazolamide

a diuretic

Sponsors & Collaborators

  • Grant S Lipman

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-08-12
Primary Completion
2017-10-01
Completion
2017-10-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03154645 on ClinicalTrials.gov